Abstract
The 5-HT1b/1d receptor agonists (the ‘triptans’) are migraine-specific agents that have revolutionised the treatment of migraine. They are usually the drugs of choice to treat a migraine attack in progress. Different triptans are available in various strengths and formulations, including oral tablets, orally disintegrating tablets, nasal sprays and subcutaneous injections. In Europe, sumatriptan is also available as a suppository.
Specific differences among the triptans exist, as evidenced by different pharmacological profiles including half-life, time to peak plasma concentrations, peak plasma concentrations, area under the concentration-time curve, metabolism and drug-drug interaction profiles. How or whether these differences translate to clinical efficacy and tolerability advantages for one agent over another is not well differentiated. However, delivery systems may play an important role in onset of action.
Given that the clinical distinctions among these agents are subtle, identification of the most appropriate triptan for an individual patient requires consideration of the specific characteristics of the patient and knowledge of patient preference, an accurate history of the efficacy of previous acute-care medications and individual features of the drug being considered. The selection of an acute antimigraine drug also depends upon the stratification of the patient’s migraine attack by peak intensity, time to peak intensity, level of associated symptoms such as nausea and vomiting, time to associated symptoms, comorbid diseases and concomitant treatments that might cause drug-drug interactions.
Individual patient response to the triptans seems to be idiosyncratic and possibly genetically determined. Therefore, a set of specific questions can be used to determine whether a currently used triptan is optimally effective, whether the dose needs to be increased or whether another triptan should be tried.
The clinician has in his/her armamentarium an ever-expanding variety of triptans, available in multiple formulations and dosages, which have good safety and tolerability profiles. Continued clinical use will yield familiarity with the various triptans, and it should become possible for the interested physician to match individual patient needs with the specific characteristics of a triptan to optimise therapeutic benefit. Use of the methods outlined in this review in choosing a triptan for an individual patient is probably more likely to lead to migraine relief than making an educated guess as to which triptan is most appropriate.
Similar content being viewed by others
References
Cady RK. Treatment strategies for migraine headache. JAMA 2001; 285: 1014–5
Humphrey PPA, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR 43175. Cephalalgia 1989; 9: 23–35
Peroutka SJ, McCarthy BG. Sumatriptan (GR43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol 1989; 163: 133–6
Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8Suppl. 7: 1–96
Humphrey PP. How it started. Cephalalgia 2001; 21Suppl. 1: 2–5
Tepper SJ, Rapoport AM. The triptans: a summary. CNS Drugs 1999; 12: 403–17
Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291–4
The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316–21
Visser WH, Vriend RH, Jaspers MW, et al. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 1996; 47: 46–51
Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831–5
Goldestein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine: the Rizatriptan Protocol 046 Study Group. Headache 1998; 38: 737–47
Oral Sumatriptan Dose-Defining Study Group. Sumatriptan: an oral dose-defining study. Eur Neurol 1991; 31: 300–5
Halpern MT, Lipton RB, Cady RK, et al. Cost-effectiveness of sumatriptan therapy: early vs delayed treatment [abstract]. Cephalalgia 2001; 21: 336
Cottrell CK, Gibson JG, Waller SW, et al. The timing of triptan use and its effect on migraine-related disability [abstract]. Cephalalgia 2001; 21: 339–40
Mansbach H. Sumatriptan: looking back and looking forward. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 183–9
Dahlõf CGH. Characteristics of different routes of administration. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 80–90
Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998; 18: 532–8
Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dose strengths. Neurology 1995; 45Suppl. 7: 5–9
Salonen R, Ashford E, Dahlof C. Intranasal sumatriptan for the acute treatment of migraine: International Intranasal Sumatriptan Study Group. J Neurol 1994; 241: 463–9
The Finnish Sumatriptan Group. A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 332–8
Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology 1997; 49: 1225–30
Kunka RL, Hussey EK, Shaw S, et al. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers. Cephalalgia 1997; 17(4): 532–40
Tepper SJ, Cochran A, Hobbs S, et al. Sumatriptan suppositories for the acute treatment of migraine. Int J Clin Pract 1998: 1: 31–5
Gõbel H. A placebo-controlled, dose-defining study of sumatriptan suppositories in the acute treatment of migraine. Front Headache Res 1997; 6: 203–6
Henriksson A. Safety and efficacy of sumatriptan suppositories in the acute treatment of migraine attacks [abstract]. Cephalalgia 1995; 15Suppl. 14: 235
Lipton RB, Pascual J, Goadsby PJ, et al. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis. Headache 2001; 41: 754–63
Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia 1994; 14: 330–8
Tepper SJ, Allen C, Sanders E, et al. Co-prescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients [abstract]. Headache 2002; 42: 397
Tepper SJ. Triptans and the potential for drug interactions. Primary Care Spec Ed 2002; 6: 1–5
Putnam GP, O’Quinn S, Bolden-Watson CE, et al. Migraine polypharmacy and the tolerability of sumatriptan: a large scale, prospective study. Cephalalgia 1999; 19: 668–75
Torres G. Zolmitriptan offers doctors and patient choices for effective treatment of migraine. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 190–8
Clement EM, Franklin M. Simultaneous measurement of zolmitriptan and its major metabolites N-desmethylzolmitriptan and zolmitriptan N-oxide in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 339–43
Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zornig, 311C90) for the acute treatment of migraine: a multicenter, double-blind, placebo-controlled, dose range-finding study: the 017 Clinical Trial Study Group. Neurology 1997; 49: 1210–8
Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997; 49: 1219–25
International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (ZOMIG, 311C90) in the acute treatment of migraine: an international study. Headache 1998; 38: 173–83
Geraud G, Olesen J, Pfaffenrath V, et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 2000; 20: 30–8
Gallagher RM. Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine [abstract]. Cephalalgia 1999; 19: 358
Becker WJ. Zolmitriptan versus sumatriptan comparison trial. Headache 2001; 41: 321–3
Tepper SJ, Donnan GA, Dowson AJ, et al. A long-term study to maximize migraine relief with Zomig. Curr Med Res Opin 1999; 15: 254–71
Dowson AJ, MacGregor EA, Purdy RA, et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002; 22: 101–6
Dowson AJ, MacGregor EA, Purdy A. Efficacy and safety of zolmitriptan 2.5 mg orally disintegrating tablet for the acute treatment of migraine [abstract]. Cephalalgia 2000; 20: 342
Edmeads J, Millson DS. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripheral HT1B/ 1D agonist. Cephalalgia 1997; 17: 41–52
Homer JJ, Maughan J, Burniston M. A quantitative analysis of the intranasal delivery of topical nasal drugs to the middle meatus: spray versus drop administration. J Laryngol Otol 2002; 116: 10–3
Dowson AJ, Boes-Hansen S, Farkkila AM. Zolmitriptan nasal spray is fast-acting and highly effective in the acute treatment of migraine [abstract]. Eur J Neurol 2001; 7Suppl. 3: 82
Abu-Shakra S, Wilmington DE, Yates RA, et al. Distribution and pharmacokinetics of zolmitriptan following administration by nasal spray [abstract]. Neurology 2002; 58: 91–2
Salonen R. Naratriptan: the gentle triptan. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 228–35
Klassen A, Elkind A, Asgharnejad M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, parallel group, study. Headache 1997; 37: 640–5
Mathew NT, Mahnaz A, Peykamian M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine: results of a double-blind, placebo-controlled, crossover study. Neurology 1997; 49: 1485–90
Goadsby PJ, Asgharnejad M, Winter PD. Twenty-four hour maintenance of headache relief after treatment of migraine with naratriptan tablets: a review of data from controlled clinical trials [abstract]. Headache 1998; 38: 382
Dahlõf C, Winter P, Whitehouse H, et al. Randomized, double-blind, placebo controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine. Neurology 1997; 48Suppl. 3: 85–6
Bomhof MK, Legg N, Paz J. Comparison of rizatriptan 10 mg versus naratriptan 2.5 mg in migraine [abstract]. Headache 1999; 39: 344
Hargreaves RJ. Pharmacology and potential mechanisms of action of rizatriptan. Cephalalgia 2000; 20Suppl. 1: 2–9
Allen C. Rizatriptan: clinical update. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 199–205
Vyas KP, Halpin RA, Geer LA, et al. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab Dispos 2000; 28: 89–95
Teall J, Tuchman M, Cutler N, et al. Rizatriptan (Maxalt) for the acute treatment of migraine and migraine recurrence: a placebo controlled, outpatient study. Headache 1998; 38: 281–7
Diener HC, Pascual J, Vega P. Comparison of rizatriptan 10 mg versus zolmitriptan 2.5 mg in migraine [abstract]. Headache 1999; 39: 351
Saxena PR. Pharmacodynamics of triptans. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 72–9
Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001; 57: 1377–83
Tfelt-Hansen P, Ryan RE. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan: a review of four randomized, double-blind clinical trials. Neurology 2000; 55Suppl. 2: 19–24
Pascual J. Almotriptan. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 247–52
Fernandes FJ, Jansat JM, Cabarrocas X, et al. Absolute bioavailability of oral and subcutaneous almotriptan [abstract]. Cephalalgia 1999; 23: 363
Cabarrocas X, Zayas JM, Suris M. Equivalent efficacy of oral almotriptan, a new 5-HT agonist, compared with sumatriptan 100 mg. Headache 1998; 38: 377–8
Pascual J, Falk J, Docekal P, et al. The tolerability and efficacy of almotriptan in long-term treatment of migraine. Eur Neurol 2001; 45(4): 206–13
Bardsley-Elliott A, Noble S. Eletriptan. CNS Drugs 1999; 12: 325–33
Gupta P, Napier CM, Purdy J, et al. In vitro profile of eletriptan, a new 5-HT1d —like receptor partial agonist [abstract]. Cephalalgia 1996; 16: 368
Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000; 54: 156–63
Stark R, Dahlõf C, Haughie S, et al. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002; 22: 23–32
Sandrini G, Färkkilä M, Burgess G, et al. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002; 59: 1210–7
Buchan P, Keywood C, Ward C. The pharmacokinetics of frovatriptan (VML 251/SB209509) in male and female subjects [abstract]. Func Neurol 1998; 13: 177
Keywood C. Frovatriptan: simplifying clinical practice in migraine. In: Humphrey P, Ferrari M, Olesen J, editors. The triptans: novel drugs for migraine. New York: Oxford University Press, 2001: 253–61
Geraud G. The acute treatment of migraine with frovatriptan. Monogr Clin Neurosci 2000; 17: 206–15
Rapoport AM, Tepper SJ. Triptans are all different. Arch Neurol 2001; 58: 1479–80
Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000; 60: 1259–87
Welch KM, Saiers J, Salonen R. Triptans and coronary spasm. Clin Pharmacol Ther 2000; 68: 337–8
MacIntyre PD, Bhargava B, Hogg KJ, et al. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 1993; 87: 401–5
Acknowledgements
This study was conducted without financial support. The authors have participated in research and/or lectures sponsored by GlaxoSmithKline, AstraZeneca, Merck Sharpe & Dohme, Pfizer and other major pharmaceutical companies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rapoport, A.M., Tepper, S.J., Bigal, M.E. et al. The Triptan Formulations. CNS Drugs 17, 431–447 (2003). https://doi.org/10.2165/00023210-200317060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200317060-00005